key: cord-0712434-40hndpiv authors: Jiao, Xiaofei; Wang, Ya; Liu, Dan; Zeng, Shaoqing; Chi, Jianhua; Li, Ruyuan; Yu, Yang; Yu, Ruidi; Wang, Siyuan; Yuan, Yuan; Gao, Yue; Xu, Sen; Li, Chunrui; Gao, Qinglei title: A real‐world study of glucocorticoid treatment in COVID‐19 patients with different disease severities date: 2020-12-08 journal: Clin Transl Med DOI: 10.1002/ctm2.235 sha: cc593bb2d02e6881a3beb05be419b1ab2f52d881 doc_id: 712434 cord_uid: 40hndpiv nan The dramatic rise in confirmed coronavirus disease 2019 (COVID-19) cases poses a rigorous challenge to the global healthcare system. Previous studies have indicated that the cytokine storm plays a major role in the progression and death of patients diagnosed with COVID-19. 1, 2 Therefore, glucocorticoids as an immunomodulatory therapy may be beneficial. 3, 4 However, evidence concerning glucocorticoids for patients with COVID-19 is controversial and limited by small sample sizes or flawed study designs. [5] [6] [7] [8] [9] A recent randomized controlled trial (RCT) showed that 6 mg of dexamethasone once per day for ten days reduced deaths by one-third in ventilated COVID-19 patients. 10 However, the practical application of glucocorticoids in clinical treatment has not been clearly stated. Considering the gap between RCT participants and actual clinical users, we believe it is of great value to explore the application of glucocorticoids and their effectiveness on patient prognosis in the real world based on elaborated information from electronic medical records. Herein, we implemented a real-world, multicenter study with comprehensively detailed clinical data of 2044 patients with COVID-19 who had been discharged or died from January 27 to March 21, 2020 in the Sino-French New City campus and the Optical Valley Campus of Tongji Hospital in Wuhan, China. All patients were classified into the noncritical group or critical group based on their most severe condition during the entire course of disease (Supporting Information Methods). The flowchart is shown in Figure S1 . We aimed to depict the administration of glucocorticoids in a large population. We employed multivariate logistic regression and Cox regression to explore whether glucocorticoids affect the prognosis of patients with COVID-19. The detailed demographic and clinical characteristics of patients with different severities are shown in Tables S1 and S2. The use of glucocorticoids was heterogeneous in patients in the two groups. Glucocorticoids were especially widely used in critical patients compared with noncritical A further comparison between glucocorticoid users and nonusers is presented in Table 1 . In the noncritical patients, the instability of vital signs in users was noticeable, including higher temperature (P < .001), faster respiratory rate (P < .001), lower mean arterial pressure (P = .009), and reduced SpO2 (P < .001). More antibiotics and intravenous immunoglobin were received by users than by nonusers (P < .001; P < .001, respectively). The mortality rates of the users and nonusers were similar (0.7% vs 0.2%, P = .168). However, the incidence of various complications of the users was significantly higher. The median hospital length of stay was significantly prolonged by nearly one week in users (24.0, IQR: 19.0-32.0 vs 18.0, IQR: 12.0-25.0, P < .001), as well as the time from illness onset to discharge or death (36.0, IQR: 29.0-43.0 vs 35.0, IQR: 27.0-43.0, P = .003). In the critical patients, the mortality rates were 84.8% for users and 88.6% for nonusers. Similar to noncritical patients, more users received intravenous immunoglobin treatment (P = .001). This finding suggested that immunomodulatory therapy may be an important method to treat COVID-19. The users among critical patients also experienced a remarkably prolonged hospital length of stay (12.0, IQR: 6.5-21. Some potential factors were found to influence the effectiveness of glucocorticoids in critical patients. The detailed results are displayed in Table 2 . This suggested that abnormal metabolism and coagulation function are related to adverse outcomes of glucocorticoid treatment. The initial levels of C reactive protein, ferritin, procalcitonin, interleukin-2R, interleukin-6, interleukin-8, interleukin-10, and tumor necrosis factor-α were remarkably higher in nonsurvivors (P < .050), which revealed that the release of excessive inflammatory factors may also influence the effectiveness of glucocorticoids. More research is needed to explore the underlying mechanism and the interaction between cytokines and glucocorticoids. In summary, highly heterogeneous individuals vary in their response to glucocorticoid treatment. Even for patients with the same disease severity, physicians should fully grasp the auxil-iary examination results of COVID-19 patients before the administration of glucocorticoids. We found no association between glucocorticoids and death, the incidence of complications, the incidence of more than one complication, or the use of invasive mechanical ventilation/extracorporeal membrane oxygenation (ECMO) in the multivariate logistic regression analysis (Table S3 ). In the multivariable Cox regression model, glucocorticoid therapy failed to affect the survival time of patients in the noncritical group (P = .558, Table S4 ) or critical group (P = .113, Table S4 ; log-rank P = .15, Figure S2 ). Incredibly, glucocorticoid treatment prolonged the hospital length of stay of both noncritical patients (HR [hazard ratio]= 0.563, 95% CI [confidence interval]: 0.504-0.628, P < .001, after adjusting for age) and critical patients (HR = 0.080, 95% CI: 0.024-0.262, P < .001). Kaplan-Meier curves with log-rank tests drew consistent conclusions (log-rank P < .0001 for noncritical patients; log-rank P < .0001 for critical patients) ( Figure 1A,B) . Furthermore, delayed viral shedding time in noncritical patients (HR = 0.892, 95% CI: 0.798-0.997, P = .043) was observed after adjusting for age and time from illness onset to admission (Table S4) B, Using glucocorticoids prolonged the median hospital length of stay of patients in the critical group in log-rank test (log-rank P < .0001). C, Using glucocorticoids did not prolong the median viral shedding time of patients in the noncritical group in log-rank test (log-rank P = .49). D, Using glucocorticoids did not prolong the median viral shedding time of patients in the critical group in log-rank test (log-rank P = .57) viral shedding time in either noncritical (log-rank P = .49, Figure 1C ) or critical patients (log-rank P = .57, Figure 1D ). Our research has several limitations. First, retrospective research has inherent limitations. However, compared with RCT, this study covered a wider population, including all confirmed patients. Second, all patients were located in Wuhan, China. Therefore, national or worldwide experience in treating COVID-19 with glucocorticoids is needed to support our findings. In conclusion, we conducted a real-world study of the early administration of glucocorticoids in patients with COVID-19 in Wuhan, China. Glucocorticoids were used in noncritically ill patients with unstable vital signs and the majority of critically ill patients. The use of glucocorticoids was related to prolonged hospitalization time of patients with different disease severities and prolonged viral shedding time of patients in the noncritical group. Glucocorticoids should be used with caution, especially in noncritical patients with older age and delayed admission. Physicians should prudently prescribe glucocorticoids according to the clinical guidelines and the actual situation of individual patients. This study was approved by the Research Ethics Commission of Tongji Hospital of Huazhong University of Science and Technology (TJ-IRB20200406) with written informed consent waived. The trial has been registered in Chinese Clinical Trial Registry (ChiCTR2000032161). Data supporting the findings of this study are available from the corresponding author upon reasonable request. The data containing information that could compromise research participant privacy, and so are not publicly available. Chunrui Li and Qinglei Gao had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Xiaofei Jiao, Ya Wang, Dan Liu, and Shaoqing Zeng equally contributed to this work. Dan Liu and Qinglei Gao designed the study. Jianhua Chi, Ruyuan Li, Yang Yu, Shaoqing Zeng, Ruidi Yu, Siyuan Wang, Yuan Yuan, Yue Gao, and Sen Xu acquired, analyzed, and interpreted the data. Xiaofei Jiao, Ya Wang, Dan Liu, and Shaoqing Zeng analyzed and interpreted data, and wrote the paper. Chunrui Li and Qinglei Gao provided critical revision of the manuscript for important intellectual content and administrative, technical, or material support. Chunrui Li and Qinglei Gao supervised this work. All authors vouch for the respective data and analysis, approved the final version, and agreed to publish the manuscript. Cytokine levels in critically Ill patients with COVID-19 and other conditions COVID-19: consider cytokine storm syndromes and immunosuppression Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: a single-center experience Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Dexamethasone in hospitalized patients with covid-19 -preliminary report The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.